Well prepared for the flu season: diagnostics in the interest of public health At regular intervals, sometimes daily, the latest influenza figures are published. National health authorities around the world collect a variety of patient data. The data are compared with each other or with data from the previous week or from the same time […]
Myasthenia gravis (MG) is an autoimmune-mediated myasthenic disorder with the main symptom of exertion-related muscle weakness. The disease results from functional loss of the nicotinic acetylcholine receptors (AChR) at the motor end plate due to attacks of different autoantibodies (AAb). Autoantibodies against nicotinic AChR are detected in around 80% of MG patients. AAb against muscle-specific
At the end of last year, EUROIMMUN and Xpedite Diagnostics announced the start of a strategic partnership. Now the time has come: EUROArray SwiftX-traction is a rapid extraction procedure enabling the isolation of pathogen DNA for further analysis using EUROIMMUN’s EUROArrays. It has been especially developed for EUROIMMUN and is now approved worldwide for diagnostic
Currently, many patients are presenting themselves at the doctor’s with symptoms of the common cold, such as cough, runny nose, headache and fever. These symptoms are typical of this time of year and can be caused by a number of different pathogens. In many cases, only differential diagnostics can help to identify the pathogen and
On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency announced their positive opinion on the marketing authorisation of lecanemab (monoclonal anti-beta-amyloid antibody; trade name: Leqembi from Eisai and Biogen) in the European Union for the treatment of early Alzheimer’s disease in Europe. In 2023, the drug
